Skip to main content
OpenTrials
Completed

NCT Number: NCT05881512

Early Feasibility Study of Transcutaneous Upper Airway Stimulation in Obstructive Sleep Apnea

Early feasibility study to estimate the functionality of a novel intervention based on non-invasive transcutaneous electrical stimulation of the hypoglossal nerve to reduce the Apnea Hypopnea Index (AHI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

United Diagnostics

Commack, New York, 11725, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 years or older
  • In good general health, as evidenced by medical history and diagnosed with moderate or severe OSA
  • In-lab PSG, within the last 6 months, with an AHI of 15-50/hour. In addition, <25% of the respiratory events on the diagnostic PSG can be attributed to central apneas
  • BMI less than or equal to 32

Exclusion criteria

  • No or mild OSA (AHI <15/h) or very severe OSA (AHI >50/hour), exclusively postural sleep apnea, or isolated Rapid-Eye-Movement (REM) sleep associated OSA.
  • Patients who are cachectic (BMI <18.5 kg/m2) or obese (BMI >32 kg/m2).
  • Patients should not have enlarged tonsils (size 3-4) and/or adenoids, nasal polyps, neuromuscular disease, hypoglossal nerve palsy, abnormal pulmonary function tests, severe pulmonary hypertension, valvular heart disease, heart failure (New York Heart Association, NYHA III-IV), recent myocardial infarction, significant cardiac arrhythmias, atrial fibrillation, stroke, opioid usage, uncontrolled hypertension, known allergic reaction to adhesives or latex, active psychiatric disease, co-existing non-respiratory sleep disorder, pregnancy or significant metal implants or cardiac/other pacemakers.
  • Patients with facial hair that affects the correct placement of the electrodes, if they are unwilling to shave.

Treatment and study plan

Transcutaneous Upper Airway Stimulation Device

Device

Multiple frequency stimulation of the hypoglossal nerve

Other names: TUAS

Primary outcomes

  1. Apnea Hypopnea Index

    Time frame: Overnight (day 1)

    Episodes of apnea and/or hypopnea scored during the course of sleep study

Secondary outcomes

  1. Arterial Oxygen Saturation (SaO2)

    Time frame: Overnight (day 1)

    SaO2 levels during the course of sleep study compared to baseline

Other outcomes

  1. Sleep Quality

    Time frame: Overnight (day 1)

    Subjective Questionnaire

Sponsors and collaborators

Lead sponsor

Somnial Inc

Industry

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
May 31, 2023
Registry last updated
May 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.